Stock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential

Stock Track11-09

Shares of 89Bio, Inc. (ETNB) surged 5.32% on Thursday, November 8th, despite the biopharmaceutical company reporting mixed results for the third quarter of 2024. The stock's rally came as investors appeared to look past the company's larger-than-expected loss and focused on potential positive signs for the future.

According to the earnings report, 89Bio posted an adjusted loss of $1.39 per share for the quarter ended September 30, wider than analysts' consensus estimate of a loss of $0.64 per share. However, the company had beaten expectations in the previous quarter, suggesting it may be making progress on its drug development efforts.

While the financial results were disappointing, analysts maintained a generally positive outlook on the stock, with seven out of nine recommending a "buy" or "strong buy" rating. The average price target of $29.50 implies significant upside potential from the current levels, indicating analysts' confidence in the company's long-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172011989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 05:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172011989","market":"hk","top_or_hot":-1,"title":"Stock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential","media":"Stock Track","content":"<p>Shares of 89Bio, Inc. (ETNB) surged 5.32% on Thursday, November 8th, despite the biopharmaceutical company reporting mixed results for the third quarter of 2024. The stock's rally came as investors appeared to look past the company's larger-than-expected loss and focused on potential positive signs for the future.</p>\n\n<p>According to the earnings report, 89Bio posted an adjusted loss of $1.39 per share for the quarter ended September 30, wider than analysts' consensus estimate of a loss of $0.64 per share. However, the company had beaten expectations in the previous quarter, suggesting it may be making progress on its drug development efforts.</p>\n\n<p>While the financial results were disappointing, analysts maintained a generally positive outlook on the stock, with seven out of nine recommending a \"buy\" or \"strong buy\" rating. The average price target of $29.50 implies significant upside potential from the current levels, indicating analysts' confidence in the company's long-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-09 05:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of 89Bio, Inc. (ETNB) surged 5.32% on Thursday, November 8th, despite the biopharmaceutical company reporting mixed results for the third quarter of 2024. The stock's rally came as investors ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ETNB","symbol_name":"89Bio, Inc.","start_time":0,"source_url":"","article_id":"1172011989","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172011989","pubTimestamp":1731099863,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of 89Bio, Inc.  surged 5.32% on Thursday, November 8th, despite the biopharmaceutical company reporting mixed results for the third quarter of 2024. The stock's rally came as investors appeared to look past the company's larger-than-expected loss and focused on potential positive signs for the future.According to the earnings report, 89Bio posted an adjusted loss of $1.39 per share for the quarter ended September 30, wider than analysts' consensus estimate of a loss of $0.64 per share. Ho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ETNB":"89Bio, Inc."},"translate_title":"尽管第三季度业绩好坏参半，但由于投资者关注未来潜力，股票赛道89Bio仍飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETNB":1},"content_text":"Shares of 89Bio, Inc. (ETNB) surged 5.32% on Thursday, November 8th, despite the biopharmaceutical company reporting mixed results for the third quarter of 2024. The stock's rally came as investors appeared to look past the company's larger-than-expected loss and focused on potential positive signs for the future.\nAccording to the earnings report, 89Bio posted an adjusted loss of $1.39 per share for the quarter ended September 30, wider than analysts' consensus estimate of a loss of $0.64 per share. However, the company had beaten expectations in the previous quarter, suggesting it may be making progress on its drug development efforts.\nWhile the financial results were disappointing, analysts maintained a generally positive outlook on the stock, with seven out of nine recommending a \"buy\" or \"strong buy\" rating. The average price target of $29.50 implies significant upside potential from the current levels, indicating analysts' confidence in the company's long-term prospects.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172011989"}